Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Essential One
NCT07483827Phase 1Recruiting
- Sponsor
- Greenovation Biotech GmbH
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 12
01
Overview
Phase 1, randomised, double-blind trial of CPV-104 in Complement 3 glomerulopathy (C3G) (2 arms), sponsored by Greenovation Biotech GmbH. Primary endpoint: Incidence of severe drug reactions and serious adverse drug reactions. Started Jun 2025; status: recruiting.
02
Drugs
CPV-104
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT07483827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483827.